Cargando…

Venom Peptides, Polyphenols and Alkaloids: Are They the Next Antidiabetics That Will Preserve β-Cell Mass and Function in Type 2 Diabetes?

Improvement of insulin secretion by pancreatic β-cells and preservation of their mass are the current challenges that future antidiabetic drugs should meet for achieving efficient and long-term glycemic control in patients with type 2 diabetes (T2D). The successful development of glucagon-like pepti...

Descripción completa

Detalles Bibliográficos
Autores principales: Lodato, Michele, Plaisance, Valérie, Pawlowski, Valérie, Kwapich, Maxime, Barras, Alexandre, Buissart, Emeline, Dalle, Stéphane, Szunerits, Sabine, Vicogne, Jérôme, Boukherroub, Rabah, Abderrahmani, Amar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10047094/
https://www.ncbi.nlm.nih.gov/pubmed/36980281
http://dx.doi.org/10.3390/cells12060940
_version_ 1785013835620417536
author Lodato, Michele
Plaisance, Valérie
Pawlowski, Valérie
Kwapich, Maxime
Barras, Alexandre
Buissart, Emeline
Dalle, Stéphane
Szunerits, Sabine
Vicogne, Jérôme
Boukherroub, Rabah
Abderrahmani, Amar
author_facet Lodato, Michele
Plaisance, Valérie
Pawlowski, Valérie
Kwapich, Maxime
Barras, Alexandre
Buissart, Emeline
Dalle, Stéphane
Szunerits, Sabine
Vicogne, Jérôme
Boukherroub, Rabah
Abderrahmani, Amar
author_sort Lodato, Michele
collection PubMed
description Improvement of insulin secretion by pancreatic β-cells and preservation of their mass are the current challenges that future antidiabetic drugs should meet for achieving efficient and long-term glycemic control in patients with type 2 diabetes (T2D). The successful development of glucagon-like peptide 1 (GLP-1) analogues, derived from the saliva of a lizard from the Helodermatidae family, has provided the proof of concept that antidiabetic drugs directly targeting pancreatic β-cells can emerge from venomous animals. The literature reporting on the antidiabetic effects of medicinal plants suggests that they contain some promising active substances such as polyphenols and alkaloids, which could be active as insulin secretagogues and β-cell protectors. In this review, we discuss the potential of several polyphenols, alkaloids and venom peptides from snake, frogs, scorpions and cone snails. These molecules could contribute to the development of new efficient antidiabetic medicines targeting β-cells, which would tackle the progression of the disease.
format Online
Article
Text
id pubmed-10047094
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100470942023-03-29 Venom Peptides, Polyphenols and Alkaloids: Are They the Next Antidiabetics That Will Preserve β-Cell Mass and Function in Type 2 Diabetes? Lodato, Michele Plaisance, Valérie Pawlowski, Valérie Kwapich, Maxime Barras, Alexandre Buissart, Emeline Dalle, Stéphane Szunerits, Sabine Vicogne, Jérôme Boukherroub, Rabah Abderrahmani, Amar Cells Review Improvement of insulin secretion by pancreatic β-cells and preservation of their mass are the current challenges that future antidiabetic drugs should meet for achieving efficient and long-term glycemic control in patients with type 2 diabetes (T2D). The successful development of glucagon-like peptide 1 (GLP-1) analogues, derived from the saliva of a lizard from the Helodermatidae family, has provided the proof of concept that antidiabetic drugs directly targeting pancreatic β-cells can emerge from venomous animals. The literature reporting on the antidiabetic effects of medicinal plants suggests that they contain some promising active substances such as polyphenols and alkaloids, which could be active as insulin secretagogues and β-cell protectors. In this review, we discuss the potential of several polyphenols, alkaloids and venom peptides from snake, frogs, scorpions and cone snails. These molecules could contribute to the development of new efficient antidiabetic medicines targeting β-cells, which would tackle the progression of the disease. MDPI 2023-03-20 /pmc/articles/PMC10047094/ /pubmed/36980281 http://dx.doi.org/10.3390/cells12060940 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Lodato, Michele
Plaisance, Valérie
Pawlowski, Valérie
Kwapich, Maxime
Barras, Alexandre
Buissart, Emeline
Dalle, Stéphane
Szunerits, Sabine
Vicogne, Jérôme
Boukherroub, Rabah
Abderrahmani, Amar
Venom Peptides, Polyphenols and Alkaloids: Are They the Next Antidiabetics That Will Preserve β-Cell Mass and Function in Type 2 Diabetes?
title Venom Peptides, Polyphenols and Alkaloids: Are They the Next Antidiabetics That Will Preserve β-Cell Mass and Function in Type 2 Diabetes?
title_full Venom Peptides, Polyphenols and Alkaloids: Are They the Next Antidiabetics That Will Preserve β-Cell Mass and Function in Type 2 Diabetes?
title_fullStr Venom Peptides, Polyphenols and Alkaloids: Are They the Next Antidiabetics That Will Preserve β-Cell Mass and Function in Type 2 Diabetes?
title_full_unstemmed Venom Peptides, Polyphenols and Alkaloids: Are They the Next Antidiabetics That Will Preserve β-Cell Mass and Function in Type 2 Diabetes?
title_short Venom Peptides, Polyphenols and Alkaloids: Are They the Next Antidiabetics That Will Preserve β-Cell Mass and Function in Type 2 Diabetes?
title_sort venom peptides, polyphenols and alkaloids: are they the next antidiabetics that will preserve β-cell mass and function in type 2 diabetes?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10047094/
https://www.ncbi.nlm.nih.gov/pubmed/36980281
http://dx.doi.org/10.3390/cells12060940
work_keys_str_mv AT lodatomichele venompeptidespolyphenolsandalkaloidsaretheythenextantidiabeticsthatwillpreservebcellmassandfunctionintype2diabetes
AT plaisancevalerie venompeptidespolyphenolsandalkaloidsaretheythenextantidiabeticsthatwillpreservebcellmassandfunctionintype2diabetes
AT pawlowskivalerie venompeptidespolyphenolsandalkaloidsaretheythenextantidiabeticsthatwillpreservebcellmassandfunctionintype2diabetes
AT kwapichmaxime venompeptidespolyphenolsandalkaloidsaretheythenextantidiabeticsthatwillpreservebcellmassandfunctionintype2diabetes
AT barrasalexandre venompeptidespolyphenolsandalkaloidsaretheythenextantidiabeticsthatwillpreservebcellmassandfunctionintype2diabetes
AT buissartemeline venompeptidespolyphenolsandalkaloidsaretheythenextantidiabeticsthatwillpreservebcellmassandfunctionintype2diabetes
AT dallestephane venompeptidespolyphenolsandalkaloidsaretheythenextantidiabeticsthatwillpreservebcellmassandfunctionintype2diabetes
AT szuneritssabine venompeptidespolyphenolsandalkaloidsaretheythenextantidiabeticsthatwillpreservebcellmassandfunctionintype2diabetes
AT vicognejerome venompeptidespolyphenolsandalkaloidsaretheythenextantidiabeticsthatwillpreservebcellmassandfunctionintype2diabetes
AT boukherroubrabah venompeptidespolyphenolsandalkaloidsaretheythenextantidiabeticsthatwillpreservebcellmassandfunctionintype2diabetes
AT abderrahmaniamar venompeptidespolyphenolsandalkaloidsaretheythenextantidiabeticsthatwillpreservebcellmassandfunctionintype2diabetes